AAPG Ascentage Pharma Group International

$30.76

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

As Ascentage Pharma Group International approaches its earnings announcement on August 20, the market's attention is drawn to its strategic focus on innovative oncology treatments, a sector that has seen significant investor interest. Despite the absence of recent financial disclosures, the company's market cap of approximately $3.88 billion underscores its potential in the biotech industry. Analysts are anticipating an EPS of $0.00, aligning with the whisper number, which suggests a cautious yet stable outlook for this period. While revenue estimates remain unavailable, the company's ongoing research and development efforts could be pivotal in shaping future financial performance. Investors will be keen to see how Ascentage Pharma leverages its strategic initiatives to drive growth and meet market expectations in the competitive landscape of cancer therapeutics.

Updated On 11/21/2025

About Ascentage Pharma Group International

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company is headquartered in Suzhou, China.

Website: https://www.ascentage.cn

Sector
TECHNOLOGY
Industry
GENERAL
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
nan
Address
NONE
Valuation
Market Cap
$6.35B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
60.58
Performance
EPS
$-0.17
Dividend Yield
—
Profit Margin
-39.90%
ROE
-52.40%
Technicals
50D MA
$17.97
200D MA
$17.97
52W High
$24.02
52W Low
$16.50
Fundamentals
Shares Outstanding
348M
Target Price
$nan
Beta
1.00

AAPG EPS Estimates vs Actual

● Estimated
● Actual

AAPG News & Sentiment

Nov 19, 2025 • Benzinga NEUTRAL
Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025 - Ascentage Pharma Group ( NASDAQ:AAPG )
ROCKVILLE, Md. and SUZHOU, China, Nov. 19, 2025 ( GLOBE NEWSWIRE ) -- Ascentage Pharma Group International ( NASDAQ:AAPG, HKEX: 6855 ) ) ( "Ascentage Pharma" or the "Company" ) , a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and ...
Nov 10, 2025 • Benzinga SOMEWHAT-BULLISH
This Hasbro Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Ascentage Pharma Group ( NASDAQ:AAPG ) , Hasbro ( NASDAQ:HAS )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Nov 05, 2025 • Benzinga SOMEWHAT-BULLISH
This Docebo Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Wednesday - CervoMed ( NASDAQ:CRVO ) , Ascentage Pharma Group ( NASDAQ:AAPG )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Nov 04, 2025 • GlobeNewswire NEUTRAL
Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025
ROCKVILLE, Md. and SUZHOU, China, Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Ascentage Pharma Group International Inc. ( NASDAQ: AAPG. HKEX: 6855 ) , a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated ...
Nov 04, 2025 • GlobeNewswire NEUTRAL
Ascentage Pharma to Present Data from Multiple Studies of Olverembatinib, Including the First Dataset from POLARIS-1 Study, at ASH 2025
ROCKVILLE, Md. and SUZHOU, China, Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Ascentage Pharma Group International Inc. ( NASDAQ: AAPG. HKEX: 6855 ) , a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated ...
Nov 04, 2025 • Benzinga NEUTRAL
Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025 - Ascentage Pharma Group ( NASDAQ:AAPG )
ROCKVILLE, Md. and SUZHOU, China, Nov. 03, 2025 ( GLOBE NEWSWIRE ) -- Ascentage Pharma Group International Inc. ( NASDAQ:AAPG, HKEX: 6855 ) ) , a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated ...
Sentiment Snapshot

Average Sentiment Score:

0.138
49 articles with scored sentiment

Overall Sentiment:

Neutral

AAPG Reported Earnings

Financials